<DOC>
	<DOCNO>NCT02843763</DOCNO>
	<brief_summary>As early complication transplantation ( acute rejection infection ) good control survival kidney transplant increase , chronic complication immunosuppression become increase challenge . The incidence cancer greatly increase transplant cancer first cause death . The iatrogenic immunosuppression play major role increase incidence cancer . If accept incidence cancer generally increase transplantation , increase risk different specific cancer another . Furthermore specific treatment tumor ( surgery , radiotherapy , chemotherapy , biotherapy ) , specificity context transplantation relate possibility modulation immunosuppression . However , immunological marker predict effectiveness modification immunosuppression . Several study point important role CD4 T cell Th1 anti-tumor immunosurveillance group cancer . Identified `` helper '' degenerate peptide , call Universal Cancer Peptide ( UCP ) derivative telomerase , type tumor antigen universal . These UCP peptide bind HLA-DR allele frequent population particularity specifically stimulate CD4 T cell type Th1 . Using test base UCP , possible detect presence spontaneous CD4 Th1 anti-UCP answer several type human cancer . The main objective study determine whether , renal transplant patient , occurrence cancer associate deficiency CD4 Th1 response anti-hTERT .</brief_summary>
	<brief_title>Study Specific CD4 Tumors Th1 Responses Renal Transplant After Occurrence Cancer</brief_title>
	<detailed_description />
	<criteria>Men woman age 18 80 year include Signature inform consent participation indicate subject understood purpose procedure require study agree participate study comply requirement limitation inherent study Join French social security receiving plan Group 1A : renal transplant patient report first cancer ( type cancer except skin ) Group 1B : renal transplant patient without cancer ( matched patient group 1A ) 1C Group : Non transplant patient report first cancer ( patient match Group 1A type stage cancer status CMV / EBV ) Group 2A : Kidney transplant patient report single squamous cell carcinoma Group 2B : renal transplant patient multiple recurrence squamous cell carcinoma . Legal incapacity limit legal capacity Topic unlikely cooperate study / low early cooperation investigator Without health insurance Topic Pregnant woman Inability understand reason study ; psychiatric disorder judge investigator incompatible inclusion study Active infection HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>